title: Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide.
abstract: Biochemical markers of bone turnover were studied in prepubertal school children with asthma in two randomized double-blind crossover trials with run-in, treatment, and wash-out periods of 2 weeks. One group (n = 11) was treated with 2.5 and 5.0 mg prednisolone, the other (n = 14) with 200 and 800 micrograms inhaled budesonide per day. Serum osteocalcin, serum total alkaline phosphatase, fasting urinary excretion of hydroxyproline and calcium, serum 25-hydroxyvitamin D, and 1,25 dihydroxyvitamin D were assessed. A dose-related reduction of serum osteocalcin (Page's test for trend: P = 0.04; z = -2.3) and of the fasting urinary hydroxyproline:creatinine ratio (Page's test for trend: P = 0.05; z = -2.0) was found in the children who were treated with prednisolone. Inhaled budesonide was not associated with statistically significant effects on any of the biochemical markers. Short-term treatment with low daily doses of prednisolone may cause a suppression of bone turnover in children with asthma. To reduce the risk of adverse effects on bone turnover, doses of inhaled budesonide up to 800 micrograms daily may be preferable to low doses of prednisolone. Bone turnover remains to be evaluated during long-term treatment.
authors.affiliation: Department of Paediatrics, Kolding Hospital, Denmark.
authors.forename: O D
authors.initials: OD
authors.lastname: Wolthers
authors.forename: B J
authors.initials: BJ
authors.lastname: Riis
authors.forename: S
authors.initials: S
authors.lastname: Pedersen
mesh_terms: D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000280:Administration, Inhalation; D000284:Administration, Oral; D000293:Adolescent; D000469:Alkaline Phosphatase / Q000097:blood / Q000187:drug effects; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001846:Bone Development / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced* / Q000378:metabolism; D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019819:Budesonide; D002112:Calcifediol / Q000097:blood; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000652:urine; D002648:Child; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000187:drug effects / Q000652:urine; D008297:Male; D015675:Osteocalcin / Q000097:blood / Q000187:drug effects; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D011282:Pregnenediones / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D001993:Bronchodilator Agents; D011282:Pregnenediones; D015675:Osteocalcin; D015652:25-Hydroxyvitamin D 2; D019819:Budesonide; D011239:Prednisolone; D003404:Creatinine; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002112:Calcifediol; D006909:Hydroxyproline; D002118:Calcium